CryoCath CE-marks 7F cardiac cryoablation device:
This article was originally published in Clinica
Executive Summary
Canada's CryoCath Technologies has CE-marked for sale in Europe its 7F Freezor catheter cryoablation system for treating cardiac tachyarrhythmias (rapid and irregular heartbeats). As well as being smaller and easier to handle than the company's earlier 9F Freezor product, which was CE-marked last year, the 7F system provides 40% more cooling capacity to treat tachyarrhythmias faster and more effectively, Steve Arless, CryoCath's president and CEO, told Clinica. The new product will be introduced into 20 leading centres this year, with a more widespread commercial launch planned for 2002, says the Kirkland, Quebec firm.
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.